Eutilex develops immunotherapy technologies, including anti-tumor T cell therapy and antibody therapeutics, to treat incurable diseases. Their focus on T cell and CAR-T therapies aims to provide effective treatment options for patients with resistant and untreatable conditions.
Funding
$18.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing treatments, leaving patients with limited options. Traditional approaches may not effectively target the tumor microenvironment or harness the patient's own immune system to fight the disease.
Solution
Eutilex is developing a range of immunotherapies, including T cell therapies, CAR-T cell therapies, and antibody therapeutics, designed to overcome resistance and provide more effective treatment options for patients with difficult-to-treat cancers. Their approach focuses on harnessing and enhancing the patient's own immune system to target and eliminate cancer cells. By targeting the tumor microenvironment and stimulating a robust T cell response, Eutilex aims to provide durable remissions and improved outcomes.
Target Audience
The primary target audience includes patients with advanced or refractory cancers who have failed to respond to standard treatments, as well as oncologists and hematologists seeking innovative therapeutic options.
Features
- 4-1BB-enhanced T cell therapy (4-1BB CTL) platform for enhanced T cell activation and persistence.
- CAR-T cell therapy programs targeting specific tumor-associated antigens.
- Antibody therapeutics designed to modulate the immune response and target cancer cells directly.
- Focus on developing therapies for solid tumors and hematological malignancies.
- Proprietary technologies to improve T cell trafficking to the tumor site.